Drug intelligence / Profile preview

VENOX

Development stage: Unknown
Lead developer: Inmunotek
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intravenous

Overview

VENOX is an allergy vaccine developed by Inmunotek S.L. It is indicated for the treatment of Hymenoptera venom allergy, specifically targeting venoms from Vespula spp. (wasp) and Apis mellifera (bee). The vaccine is used in immunotherapy to induce tolerance and reduce the severity of allergic reactions to stings in real-life conditions.

Brand names: VENOX

Targets

IgE (Immunoglobulin E)Honey bee venom allergens

Beyond the preview

Go deeper on VENOX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VENOX.

Explore the full profile